

News Releases

All Years

Search

Go

[Advanced Search](#)

MAR 24, 2022

Inhibrx Announces Details of Presentations at 2022 AACR Annual Meeting

MAR 3, 2022

Inhibrx Receives FDA Orphan-Drug Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

FEB 28, 2022

Inhibrx Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Recent Corporate Highlights

FEB 22, 2022

Inhibrx Announces Amended Loan Agreement with Oxford

JAN 4, 2022

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

DEC 1, 2021

Inhibrx Receives FDA Orphan-Drug Designation for

INBRX-109 in Chondrosarcoma

NOV 9, 2021

Inhibrx Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights

NOV 3, 2021

Inhibrx Announces Presentations at SITC 2021

NOV 1, 2021

Inhibrx Announces Participation in Upcoming Scientific and Investor Conferences

OCT 28, 2021

Inhibrx Strengthens Leadership Team with Three Key Executive Hires and Announces Appointment of Kristiina Vuori, M.D., Ph.D. to its Board of Directors

Show  per page

«	1	2	3	4	5	6	7	»
---	-------------------	-------------------	-------------------	---	-------------------	-------------------	-------------------	---



<https://inhibrx.investorroom.com/news-releases?l=10&o=30>